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A bstract
Background: The aim o f the study was to  compare the prevalence and types o f HIV-related oral lesions between 
children and adult Tanzanian patients on HAART w ith those not on HAART and to  relate the occurrence o f the lesions 
w ith anti-HIV drug regimen, clinical stage o f HIV disease and CD4+ cell count.
Methods: Participants were 532 HIV infected patients, 51 children and 481 adults, 165 males and 367 females. Children 
were aged 2 -17 years and adults 18 and 67 years. Participants were recruited consecutively at the Muhimbili National 
Hospital (M NH) HIV clinic from  O ctober 2004 to  September 2005. Investigations included; interviews, physical 
examinations, HIV testing and enumeration o f CD4+ T cells.
Results: A  tota l o f 237 HIV-associated oral lesions were observed in 210 (39.5%) patients. Oral candidiasis was the 
commonest (23.5%), followed by mucosal hyperpigmentation (4.7%). There was a significant difference in the occurrence 
o f oral candidiasis (%2 = 4.31; df = 1; p = 0.03) and parotid enlargement (%2 = 36.5; df = 1; p = 0.04) between children and 
adults. Adult patients who were on HAART had a significantly lower risk of; oral lesions (OR = 0.32; 95% CI = 0.22 -  
0.47; p = 0.005), oral candidiasis (OR = 0.28; 95% CI = 0.18 -  0.44; p = 0.003) and oral hairy leukoplakia (OR = 0.18; 95% 
CI = 0.04 -  0.85; p = 0.03). There was no significant reduction in occurrence o f oral lesions in children on HAART (OR 
= 0.35; 95% CI = 0.11—1.14; p = 0.15). There was also a significant association between the presence o f oral lesions and 
CD4+ cell count < 200 cell/mm3 (%2 = 52.4; df = 2; p = 0.006) and w ith W H O  clinical stage (%2 = 121; df = 3; p = 0.008). 
Oral lesions were also associated w ith tobacco smoking (%2 = 8.17; df = 2; p = 0.04).
Conclusion: Adult patients receiving HAART had a significantly lower prevalence o f oral lesions, particularly oral 
candidiasis and oral hairy leukoplakia. There was no significant change in occurrence o f oral lesions in children receiving
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HAART. The occurrence o f oral lesions, in both HAART and non-HAART patients, correlated w ith W H O  clinical staging 
and CD4+ less than 200 cells/mm3.
Background
M ost African studies o n  HIV associated oral lesions have 
been done during pre-HAART era [1-11]. The relatively 
few studies o f oral lesions in  patients on  HAART have 
been conducted elsewhere and do indicate significant dif­
ferences in  the influence o f HAART on  types o f  oral 
lesions [12-14]. For example, oral candidiasis, oral hairy 
leukoplakia, Kaposi's sarcoma and  HIV-associated perio­
dontal diseases have been reported to  decrease [12,13,15­
22]. O n the other hand, HIV-salivary gland disease, 
hum an  papillom a virus (HPV)-associated oral lesions 
including papillom a, condylom as and  focal epithelial 
hyperplasia [oral warts], xerostom ia and  recurrent oral 
ulceration appear to  have increased [13-15,18,23-25]. 
There are also reports indicating no  change in  the occur­
rence o f HIV associated oral lesions in  children receiving 
HAART [26,27]. The reasons for these differences are no t 
entirely clear. Some authors have associated these varia­
tions w ith differences in  access to oral health  care, dem o­
graphic and social factors, m ode o f HIV transm ission, 
types o f co-infections, disease stage and im m une reconsti­
tu tion  [18,28,29]. Nonetheless, the presence o f such sig­
nificant differences underlines the need for m eticulous 
m onitoring o f prevalence and types o f HIV associated oral 
lesions in  every clinical setting tha t provide HAART [13].
As indicated earlier, m ost o f the above-m entioned studies 
have been conducted in  developed countries [30,31]. 
There is relatively little inform ation em anating from  
developing countries, where particular efforts are being 
m ade to  scale up  provision o f  HAART to eligible patients 
[32].
The governm ent o f Tanzania, w ith assistance from  inter­
national donor agencies, started providing HAART to HIV 
patients free o f charge in  July 2004 [33,34]. However, 
there is no  inform ation regarding hum an  im m unodefi­
ciency virus (HIV)-related oral lesions o f  patients on  
antiretroviral therapy. This study aim ed to  determ ine the 
prevalence and  types o f oral m anifestations o f HIV/AIDS 
betw een children and  adu lt patients o n  HAART and those 
n o t on  HAART, and  correlate clinical oral lesions w ith 
clinical stage o f  HIV disease, anti-HIV drug regim en and 
CD4+ cell count.
Methods
Participants and setting
A total o f 532 HIV-infected patients, 367 (69% ) females 
and 165 (31% ) males participated in  the study. There 
were 51 children aged betw een 2 and 17 years, w ith m ean
age o f  7.6 (SD ± 4.3) years and  481 adults aged 18-67  
years, w ith a m ean  age o f 38.2 (SD ± 8.9) years. Partici­
pants were recruited consecutively at the M uhim bili 
N ational Hospital (MNH) HIV clinic in  Dar es Salaam, 
from  O ctober 2004 to Septem ber 2005. The MNH is the 
largest referral hospital in  Tanzania and serves as a teach­
ing facility for the M uhim bili University College o f  Health 
Sciences (MUCHS), the largest medical school in  the 
country.
Study design and sample size calculations
This was a cross sectional study. The sam ple size was esti­
m ated at 336, by assum ing the prevalence o f oral lesions 
in  HIV infected individuals in  Tanzania to  be around 30%
[4] and by setting type I error at 5% and  type II error at 
20%. We consecutively enrolled 532 patients. N one o f the 
patients declined participation in  this study, bringing the 
participation rate to  1 0 0 %.
Investigations
Patients were interviewed using a standard structured 
questionnaire to  obtain  inform ation regarding social and 
dem ographic details, past medical history, family history 
and history o f  previous m edication. Previous episodes o f 
oral candidiasis, o ther medical conditions, use o f tradi­
tional medicine, anti-tuberculosis drugs, antifungal 
agents, and use o f antiretroviral and  current treatm ents 
were all recorded. Current and previous episodes o f 
opportunistic systemic diseases related to  HIV were cate­
gorized and  recorded as follows: tuberculosis, pneum o­
nia, herpes zoster infection and  cryptococcal meningitis.
General examination
Clinical exam ination o f all study patients was done by an 
independent physician, w ho categorized them  in  accord­
ance w ith the W orld Health O rganization (W HO) clinical 
staging criteria [35].
Oral examination
An oral exam ination was carried ou t by a qualified dental 
surgeon w ithou t know ing the HIV clinical stage and 
CD4+ cell count level o f the patien t or w hether the patient 
was on  HAART or not. A standard oral exam ination 
m ethod  recom m ended by W HO [36] was used to  exam­
ine: (a) the extra-oral, head and neck areas; and  (b), peri­
oral and  intra-oral soft tissues using a criteria described by 
Greenspan et al. [37]. Exam ination was conducted while 
the patien t was seated on  a chair under artificial light. The 
extra-oral and peri-oral tissues were exam ined first, fol­
lowed by the intra-oral tissues, for changes in  size, colour
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and shape o f anatom ical areas as well as for clinical signs 
and lesions. The oral lesions associated w ith HIV infection 
were diagnosed based on  their clinical presentation and 
where m ultiple sites were involved, all sites were docu­
m ented.
HIV serology and determination o f lymphocytes subsets
Blood was collected in  EDTA tubes from  the patients. HIV 
serology was determ ined by Vironostika HIV Uni-Form II 
Ag/Ab (BioMerieux, Boxtel, The N etherlands) and  reactive 
samples were retested by Vironostika HIV Uni-Form II 
Plus O (BioMerieux, Boxtel, The Netherlands). Samples 
reactive on  b o th  tests were considered to  be positive for 
IgG anti HIV antibodies. Enum eration o f CD4+ and CD 8 + 
T cells was done using FACS count m achine after staining 
patients' b lood  w ith m onoclonal antibodies [38].
HAART regimens
In Tanzanian setting, a triple therapy consisting o f  2 nucl­
eoside reverse transcriptase inhibitors (NRTI) + 1 n o n ­
nucleoside reverse transcriptase inhibitors (NNRTI) or 2 
NRTI + 1 Protease inh ib ito r (PI) is recom m ended. The 
first line includes four different com binations o f drugs: 
stavudine + lam ivudine + nevirapine; stavudine + lamivu- 
dine + effavirenz; zidovudine + lam ivudine + nevirapine 
and zidovudine + lam ivudine + effavirenz. The second 
line regim en includes the following drug com bination: 
Abacavir + kaletra (lopinavir/ritonavir) + didanosine and 
abacavir + saquinavir/ritonavir + didanosine [34].
Ethical issues
The study protocol was approved by the ethics com m it­
tees o f the M uhim bili University College o f  H ealth Sci­
ences and M uhim bili N ational Hospital, Dar es salaam, 
Tanzania. Inform ed verbal consent was sought from  par­
ticipants and  from  parents/or guardians in  case o f chil­
dren below  eighteen years. The following inform ation was 
given to  ensure tha t patients and  parents/guardians have 
the inform ation needed to  m ake an  inform ed choice: a 
com plete description o f  the aims o f  the study, potential 
benefits and  risks, b lood  collection procedures and  assur­
ance o f  confidentiality o f any inform ation given as well as 
test results. Study personnel provided any other requested 
additional inform ation. All patients seen in  this study 
received appropriate care and treatm ent according to 
national guidelines on  care and  treatm ent o f HIV infected 
individuals. Patients w ho were found to  have any oral 
lesions were referred to  the D epartm ent o f Oral Surgery 
and Oral Pathology o f  the M uhim bili N ational Hospital 
where appropriate m anagem ent and  follow-up were 
given. All patients' inform ation and  test results were con­
fidentially kept.
Statistical analysis
Data were coded, entered, cleaned, validated and ana­
lyzed using the SPSS version 12.0 [39]. Patients were cate­
gorized in to  children (<18 years) and adults (>18 years) 
and in to  those on  HAART and those n o t receiving HAART. 
C om parison o f proportions was perform ed using the 
Pearson chi-squared test and in  situation where 20% or 
m ore o f the cells had  expected count less than  5, Fisher's 
exact test was used. Bivariate analysis was done using 
Spearm an's rank correlations. A P-value o f < 0.05 was con­
sidered significant. The following were determined: 
degree o f associations betw een occurrence and  types o f 
oral lesions and use o f anti-retrovirals, gender, smoking 
habits, alcohol consum ption, coexistence w ith opportun­
istic systemic diseases, clinical stage o f HIV disease and 
degree o f im m unosuppression. M ultiple logistic regres­
sion analysis was perform ed to  assess the association 
betw een presence o f oral lesion associated w ith HIV and 
use o f antiretrovirals after adjusting for CD4+ cell count.
Results
A total o f 532 HIV-infected patients, 367 (69% ) females 
and 165 (31% ) m ales participated in  the study (Table 1). 
There were 51 children aged betw een 2 and 17 years, w ith 
m ean  age o f 7.6 (SD ± 4.3) years and  481 adults aged 18­
67 years, w ith a m ean  age o f  38.2 (SD ± 8.9) years. Over­
all, m edian CD4+ cell count was 151 cells/m m 3, w ith val­
ues ranging from  1 to  2007 cell/m m 3. The m edian CD4+ 
cell count for children was 501 cells/m m 3 and 134 cells/ 
m m 3 for adults. Majority 373 (70.1% ) o f  children and 
adult patients were in  the W HO clinical stages II to III. 
Am ong the participants, 298 (56% ) patients were on 
HAART, consisting o f nucleoside reverse transcriptase 
inhibitors (NRTIs), non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) and protease inhibitors (PIs). M ajor­
ity 531 (99.7% ) were on  the first line HAART com bina­
tion, o f w hom  229 (76.8% ) were on  a com bination  o f 
Stavudine/Lam ivudine/Nevirapine, 32 (10.7% ) on  a 
com bination o f Zidovudine/Lamivudine/Effavirenz, 26 
(8.7% ) on  Stavudine/Lamivudine/Effavirenz and  10 
(3.4% ) were on  Zidovudine/Lam ivudine/Nevirapine. 
O ne patien t (0.3% ) was on  second line com bination  tha t 
included protease inhibitors (Abacavir/Lopinavir/Dida- 
nosine). Two hundred  and  thirty four (44% ) patients 
were n o t receiving HAART. Sixty-two patients (11.7% ) 
reported use o f traditional medicines, o f w hom  36 (58% ) 
were concom itantly using traditional m edicines w ith 
HAART.
A total o f 237 HIV-associated oral lesions were observed 
in  210 (39.5% ) patients. Overall, oral candidiasis was the 
com m onest oral lesion seen in  125 (23.5% ) patients fol­
lowed by m ucosal hyper p igm entation 25 (4.7% ), parotid 
gland enlargem ent 21 (3.9% ) and  oral Kaposi's sarcoma
17 (3.2% ) (Table 2). In children, parotid  gland enlarge­
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T a b le  1: S o c io -d e m o g ra p h ic , t re a tm e n t ,  W H O  c lin ic a l s tage and C D 4  ce ll c o u n ts  o f  s tu d y  p a rtic ip a n ts
C h a ra c te r is t ic s A l l  p a t ie n ts  n (%) P a tie n ts  w i th  o ra l les ions n (% )* X2-va lu e p -v a lu e * *
G e n d e r
Male 165 (31.0) 63 (38.2) 0.17 0.68
Female 367 (69.o) 147 (40.1)
A g e  (Y e a rs )
C hildren 2 -17 51 (9.6) 21 (41.2) 0.68 0.88
Adults 18 -  67 481 (90.4) 189 (39.3)
S m o k in g  h a b it
C urren t 20 (3.8) l4  (70) 8.17 0.02
Stopped 17 (3.2) 7 (41.2)
Never 495 (93.0) l89  (38.2)
A lc o h o l c o n s u m p tio n
C urren t 31 (5.8) l0  (32.3)
Stopped 37 (7.0) 16 (43 .2) 0.90 0.64
Never 464 (87.2) l84  (39.6)
T r a d it io n a l m e d ic in e
Yes 62 (1 1.7) 25 (40.3) 0.17 0.68
N o 470 (88.3) l83 (38.9)
A n t i r e t r o v ir a l  th e ra p y
W ith o u t therapy 234 (44.0) l27  (54.3) 38.30 0.00
H AAR T therapy 298 (56.0) 83 (27.9)
A n t i r e t r o v i r a l  typ e s
Stav/Lamiv/Nev 229 (76.8) 9 (12.9) 2.96 0.57
Stav/Lamiv/Eff 26 (8.7) l0  (38.5)
Zido/Lamiv/Eff 32 ( l 0.7) l l  (34.4)
Z ido/Lam iv/Nev 10 (3.4) 2 (20.0)
Abac/Lop/Didan 1 (0.3) 0 (0)
W H O  H IV  c lin ic a l s tage
Stage I 70 (13.2) 9 (12.9)
Stage II 204 (38.3) 38 (18.6) 120.93 0.00
Stage III 169 (3 1 .8) l0 l  (59.8)
Stage IV 89 (16.7) 62 (69.7)
C D 4+ ce ll c o u n t (c e lls /m m 3)
> 500 46 (8.6) 10 (21.7)
200-500 164 (30.8) 33 (20.5) 52.45 0.00
< 200 322 (60.5) 167 (31.9)
T o ta l n u m b e r  o f  p a tie n ts 532 (1 0 0 .) 210 (3 9 .5 )
*  Row percentages; * *  p-value less than 0.05 was considered significant; x 2 Chi square test
m ent was the com m onest oral lesion (19.6% ), followed 
by oral candidiasis (11.8% ), oral Kaposi's sarcoma 
(3.9% ), oral hairy leukoplakia (3.9% ), herpes simplex 
lesions (2.2% ) and  oral warts was the least (2.0%). In 
adults, oral candidiasis was the com m onest (24.7% ), fol­
lowed by m ucosal hyperpigm entation (5.2% ), herpes 
zoster face and odontogenic abscess was the least (0.4% 
each). There was statistically significant difference in  the 
occurrence o f oral candidiasis (X2  = 4.31; d f = 1; p < 0.05) 
and parotid  enlargem ent (X2  = 36.5; d f = 1; p < 0.05) 
betw een children and adults. Pseudom em branous candi­
diasis was the m ost p redom inant type o f  oral candidiasis 
66.4% (83/125) followed by a com bination  o f pseu­
dom em branous and erythem atous 12% (15/125), ery­
them atous candidiasis 9.6% (12/125), angular cheilitis 
3.2% (4/125), com bination o f angular cheilitis w ith ery­
them atous and hyperplastic variant were the least ( 1 .6 %
each). Am ong 125 patients diagnosed w ith oral candidia­
sis 42 (33.6% ) patients had  previous history o f oral can­
didiasis, 37 (29.6% ) patients presented w ith esophageal 
sym ptom s such as dysphagia, odynophagia and chest 
pain  at the tim e o f exam ination.
Table 3 shows no  significant difference in  prevalence o f 
oral lesions am ong children on  HAART and  those n o t on 
HAART (OR = 0.35; 95% CI = 0.11 -  1.15; p > 0.05). Table
4 shows th a t adult patients w ho were on  HAART had  a sig­
nificantly lower risk o f  oral lesions (OR = 0.32; 95% CI = 
0 .22-0.47; p < 0.01), oral candidiasis (OR = 0.28; 95% CI 
= 0.18 -  0.44; p < 0.01) and oral hairy leukoplakia (OR = 
0.18; 95% CI = 0.04 -  0.85; p < 0.03). There was also 
lower prevalence o f necrotizing ulcerative gingivitis, her­
pes simplex lesions, recurrent ulcers, Bell's palsy and  her­
pes zoster o f face in  adult patients w ho were on  HAART,
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O ra l les ion C h ild re n  (2 -1 7  y rs ) n (%) A d u lts  (1 8 -6 7  y rs )  n (%) T  o ta l (n  =
O ra l can d id ias is 6 (1 1.8) 119 (24.7) 125 (23.5)
H y p e rp ig m e n ta t io n 0 (0) 25 (5.2) 25 (4.7)
E n la rg e d  P a ro t id  g lan d 10 (19.6) 11 (2.3) 21 (3.9)
O ra l K apo s i's  s a rc o m a 2 (3.9) 15 (3.1) 17 (3.2)
N e c ro t iz in g  U lc e ra t iv e  g in g iv it is 0 (0) 13 (2.7) 13 (2.4)
O ra l h a iry  le u k o p la k ia 2 (3.9) 10 (0.6) 12 (2.3)
H e rp e s  s im p le x  les ions 7 (2.2) 2 (2.1) 9 (1.7)
R e c u r re n t u lce rs 0 (0) 4 (0.8) 4 (0.8)
O ra l w a r ts 1 (2.0) 3 (0.6) 4 (0.8)
B e ll's  pa lsy 0 (0) 3 (0.6) 3 (0.6)
H e rp e s  zo s te r  face 0 (0) 2 (0.4) 2 (0.4)
O d o n to g e n ic  abscess 0 (0) 2 (0.4) 2 (0.4)
A l l  o ra l les ions 21 (4 1 .2 ) 189 (39 .3 ) 210 (39 .5 )
b u t the difference was n o t statistically significant (p > 
0.05). After controlling for CD4+ cell count, adult on  
HAART had  a significantly lower risk o f  oral Kaposi's sar­
com a com pared w ith those n o t on  HAART (adjusted OR 
= 0.29; 95% CI = 0.10-0 .89; p < 0.03). The odds for oral 
warts and m ucosal hyper p igm entation were non-signifi­
cant higher in  adult w ho were on  HAART, being (OR = 
1.49; 95% CI = 0.13 -  16.5; p > 0.05) and (OR = 1.62; 
95% CI = 0.68 -  3.82; p > 0.05), respectively.
The duration  o f  use o f HAART ranged from  1 to  14 
m onths, w ith m ajority (71.1% ) having been on  treatm ent 
for one to  six m onths. Patients on  HAART for the duration 
o f m ore than  six m onths had significantly lower preva­
lence o f oral lesions (OR = 0.53; 95% CI 0.29-0 .97; p <
0.05) and specifically oral candidiasis (OR = 0.53; 95% CI 
0 .29-0.97; p = 0.04).
The m ean CD4+ profiles o f patients on  HAART and those 
n o t on  HAART are show n in  Table 5. Overall, the m ajority 
(67.8% ) o f patients w ho were on  HAART had  CD4+ cell 
count < 200 cells/m m 3. O nly a small m inority (32.2% ) o f 
the patients o n  HAART were found to  have CD4+ counts > 
200 cells/m m 3. Am ong those w ho were n o t on  HAART 
51.3% had  CD4+ cell count < 200 cells/m m 3 while the rest 
in  the group had  CD4+ cell count > 200 cells/m m 3. How­
ever, the m ajority (70.3% ) o f  adult patients on  HAART 
had  CD4+ cell count < 200 cells/m m 3 while only m inority 
(36.4% ) o f  the children on  HAART had CD4+ cell count < 
200 cells/m m 3. The m ean  difference o f CD4+ cell counts
T a b le  3: C o m p a ris o n  o f  o ra l les ions a m o n g  c h ild re n  on  H A A R T  (n  = 22) and th o se  n o t on  H A A R T  (n  = 29)
T y p e  o f  o ra l le s ion s  N o . o f  o ra l les ions n (%) U n a d ju s te d  O R  (95%  C I)  A d ju s te d  O R  (95%  C I)  p -va lu e
O ra l can d id ia s is
On HAART 0 (0.0) 0.0 (0.0-9.20) 0.0 (0.0-1.80) 0.80
N o t on H AART 6 (20.7)
E n la rg e d  P a ro t id  g lan d
On HAAR T 4 (18.2) 0.8 (0.2-3.48) 0.9 (0.22-3.93) 0.82
N o t on H AART 6 (20.7 )
O ra l K apo s i's  s a rc o m a
On HAART 1 (4.5) 1.3 (0.08-22.6) 0.9 (0.05-17.4) 0.84
N o t on H AART 1 (3.4)
O ra l h a iry  le u k o p la k ia
On HAART 0 (0.0) 0.0 (0.0-2.61) 0.0 (0.0-2.11) 0.88
N o t on HAART 10 (6.9)
H e rp e s  s im p le x  les ions
On HAART 0 (0.0) 0.0 (0.0-1.52) 0.0 (0.0-7.30) 0.92
N o t on H AART 1 (3.4)
O ra l w a r ts
On HAART 1 (4.5) - - 0.91
N o t on H AART 0 (0.0)
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T y p e  o f  o ra l les ions N o . o f  o ra l le s ion s  n (%) U n a d ju s te d  O R  (95%  C I) A d ju s te d  O R  (95%  C I) p -va lu e
O ra l can d id ias is
On HAAR T 41 (14.9) 0.28 (0 .18- 0.17 (0.1 1-0.28) 0.00
N o t on HAART 78 (38.0) 0.44)
H y p e r  p ig m e n ta t io n
On HAAR T 17 (6.2) 1.62 (0 .68- 1.60 (0.67-3.81) 0.27
N o t on H AART 8 (3.9) 3.82)
E n la rg e d  P a ro t id  g lan d
On HAART 6 (2.2) 0.89 (0 .27- 0.92 (0.27-3.10) 0.85
N o t on H AART 5 (4.9) 2.95)
O ra l K apo s i's  s a rc o m a
On HAART 5 (1.8) 0.36 (0 .12- 0.29 (0.10-0.89) 0.06
N o t on HAART 10 (4.9) 1.06) *(0.03)
N e c ro t iz in g  U lc e ra t iv e  g in g iv it is
On HAART 5 (1.7) 0.45 (0.15-1.41) 0.37 (0.12-1.15) 0.17
N o t on H AART 8 (3.4)
O ra l h a iry  le u k o p la k ia
On HAART 2 (0.7) 0.18 (0 .04- 0.15 (0.03-0.70) 0.03
N o t on H AART 8 (3.9) 0.85)
H e rp e s  s im p le x  les ions
On HAART 3 (1.1) 0.44 (0 .10- 0.39 (0.09-1.69) 0.26
N o t on H AART 5 (2.4) 1.86)
R e c u r re n t u lce rs
On HAART 1 (0.4) 0.24 (0 .02- 0.22 (0.02-2.15) 0.22
N o t on H AART 3 (1.54) 2.37)
O ra l w a r ts
On HAART 2 (0.7) 1.49 (0 .13- 1.44 (0.13-16.4) 0.75
N o t on H AART 1 (0.5) 16.5)
B e ll's  pa lsy
On HAART 0 (0.0) - - 0.84
N o t on H AART 3 (1.5)
H e rp e s  z o s te r  face
On HAART 0 (0.0) - - 0.85
N o t on H AART 2 (0.9)
O d o n to g e n ic  abscess
On HAART 1 (0.4) 0.74 (0.04-11.9) 0.78 (0.05-13.0) 0.83
N o t on H AART 1 (0.5)
*  p-value obtained after adjusting fo r C D 4+ cell counts.
betw een the adult and children on  HAART and  those no t 
on  HAART was statistically significant (t = 3.94; 95% CI = 
42.3 -  126.3; p < 0.01). In b o th  HAART and non-HAART 
receiving children and adu lt patients oral lesions occurred 
m ore significantly am ong those w ith CD4+ cell count less 
than  200 cell/m m 3 ( % 2  = 52.4; d f  = 2; p < 0.01). There was 
a strong association betw een the W HO clinical stage of 
HIV disease w ith the presence o f oral lesions ( % 2  = 121; d f 
= 3; p < 0.01), particularly oral candidiasis ( % 2  = 112; d f = 
3; p < 0.01), oral Kaposi's sarcoma ( % 2  = 121; d f = 3; p < 
0.01), and oral hairy leukoplakia ( % 2  = 10; d f  = 3; p < 
0.05).
Eighty-four (15.8% ) patients had  current systemic dis­
eases at the tim e o f exam ination. Sixty-two (11.7% ) 
patients had  pulm onary tuberculosis (TB) and were on  
anti-tuberculosis treatm ent. O ther systemic opportunistic
diseases encountered at the tim e o f exam ination were; 
pneum onia 14 (2.6% ) patients and herpes zoster 8  
(1.5% ) patients. O ne hundred  and  thirty eight (25.9% ) 
reported history o f herpes zoster infection, 84 patients 
(15.8% ) pneum onia while cryptococcal m eningitis was 
reported by only 10 patients (1.9% ). There was a signifi­
cant association betw een occurrence o f pulm onary TB 
w ith oral lesions (x 2  = 6.9; d f  = 1; p < 0.01) and  oral can­
didiasis (x 2  = 1 1 .0 ; d f  = 1 ; p < 0 .0 1 ) b u t n o t o ther systemic 
diseases (P > 0.05). Oral lesions were n o t associated w ith 
any o f  the investigated socio-dem ographic features except 
for tobacco sm oking ( % 2  = 8.17; d f = 2; p < 0.01).
Discussion
In the present study, the prevalence o f  HIV-associated oral 
lesions in  adult patients receiving HAART was signifi­
cantly reduced. The reduction was m ainly attributed to
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T a b le  5: C D 4 +  c e ll c o u n ts  o f  P a tie n ts  on  H A A R T  and th o se  n o t on  H A A R T
P a tie n ts  o n  H A A R T  (n  =  298) 
n (%) M ean S D
P a tie n ts  w i th o u t  H A A R T  (n  =  234) 
n (%) M ean SD
C D 4 +  ce ll c o u n t (c e lls /m m 3) 
<200 202(67.8) 84.0 62.1 120 (51.3) 65.2 57.0
2 0 0 -5 0 0 80(26.8) 296.0 75.0 84 (35.9) 314.4 90.2
>500 16(5.4) 714.1 207.1 30 (12.8) 879.9 415.2
T o ta l 298 174.8 177.5 234 259.1 310.0 470
Student's t- te s t fo r comparing means; ( t  = 3.94; 95% CI = 42.3 -  126.3; p = 0.00).
the reduction o f  oral candidiasis and oral hairy leukopla­
kia am ong adult patients. This finding is consistent w ith 
observations in  o ther studies tha t have show n significant 
reduction in  these oral lesions associated w ith HAART 
usage, linked to  the im proved im m une status o f  patients 
[12,13,15-22]. Notably, patients on  HAART for the dura­
tion  o f m ore than  six m onths had  significantly lower prev­
alence o f oral lesions (OR = 0.53; 95% CI 0.29-0 .97; p < 
0.05) and  specifically oral candidiasis (OR = 0.53; 95% CI
0.29-0 .97; p = 0.04). There was, however, no  significant 
association betw een the type o f HAART regim en and  pres­
ence o f oral lesions, m ost probably due to the fact that 
m ost o f  our patients (76.8% ) were on  one type o f HAART 
consisting o f stavudine, lam ivudine and  nevirapine, and 
tha t only one patient had  a HAART com bination contain­
ing PI. We found no  significant difference in  prevalence of 
oral lesions betw een children on  HAART and those n o t on  
HAART (Table 3), sim ilar to  o ther studies [26,27]. The 
occurrence o f HIV-associated oral in  children is an issue 
tha t requires further investigation as the results o f  differ­
en t studies have produced conflicting results. In one study 
there was no  direct relationship betw een prevalence of 
oral lesions, severe im m unodepression, an d /o r viral load
> 1 0 0 0 0 0  copies in  children w ho were perinataly infected 
w ith HIV [40].
There were no  significant difference in  prevalence o f oral 
lesions betw een adults (39.3% ) and children (41.2% ), (p
> 0.05). However, a significantly higher prevalence of 
enlargem ent o f  parotid  glands in  children and oral candi­
diasis in  adults was observed, w hich is in  keeping w ith the 
findings o f Greenspan et al. 1992 [37].
Mucosal hyperpigm entation, w hich was the second m ost 
prevalent oral lesions after oral candidiasis w ith a preva­
lence o f 4.7%, occurred at higher, b u t non-significant 
m agnitude, am ong adult patients w ho were on  HAART. 
The reported prevalence o f m ucosal hyperpigm entation 
com pares w ith a prevalence o f 6 % am ong HIV/AIDS 
patients in  Kenya [9]. The higher prevalence o f m ucosal 
hyperpigm entation in  patients on  HAART has been linked 
w ith increased m elanin  production  in  the epithelium  
associated w ith increased release o f a-melanocyte-stimu-
lating horm one (a -  MSH) [41] as a result o f systemic 
ketoconazole and zidovudine therapy [42,43]. In the 
present study 20% (5/25) o f patients w ith m ucosal hyper­
pigm entation were on  HAART com bination containing 
zidovudine.
Likewise, there was insignificant increase in  oral papillo­
m ata [oral warts] in  patients on  HAART as com pared to 
the non-HAART group. The increase in  oral warts am ong 
patients on  HAART has been associated w ith im m une 
reconstitution [18,23-25]. The lack o f significant associa­
tion  betw een oral w art and HAART usage observed in  the 
present study could be due to the short period o f the 
adm inistration o f HAART as m ajority o f patients were on 
HAART for one to  six m onths.
There were no  differences in  the prevalence o f other oral 
lesions including enlarged parotid  glands, necrotizing 
ulcerative gingivitis, recurrent ulcers, Bell's palsy and  her­
pes zoster o f the face betw een HAART and non-HAART 
groups (p > 0.05). This could be explained by the fact tha t 
m ost o f  these lesions are classified as being less com ­
m only  associated w ith HIV [44] and  therefore, their prev­
alence even in  the non-HAART receiving group was small.
The use o f  traditional m edicine am ong our patients was 
high (11.7% ), which is approxim ately one in  eight 
patients, an observation tha t is in  line w ith th a t reported 
earlier in  Tanzania [45]. A lthough no  significant associa­
tion  was found betw een occurrences o f  oral lesions and 
use o f traditional m edicine (Table 1) there is still a need 
for further studies since m any people w ith HIV/AIDS use 
traditional m edicine in  addition  to  HAART. It is crucial to 
learn m ore abou t the nature and  com position o f these 
p lan t m edicines and  their potential interactions w ith 
drugs th a t are used for m anagem ent o f HIV/AIDS and its 
associated opportunistic diseases.
In this study, 15.8% o f patients diagnosed to  have sys­
tem ic diseases such as tuberculosis, pneum onia and her­
pes zoster at the tim e o f exam ination. However, the only 
significant association found was betw een pulm onary  TB 
and oral lesions, specifically oral candidiasis (p <= 0 .0 1 )
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T a b le  6: A ss o c ia tio n  in th e  o c c u rre n c e  o f  o ra l les ions and o p p o r tu n is t ic  sys te m ic  diseases a m o n g  H IV - in fe c te d  p a tie n ts  exp ressed  as 
O dd s  ra tio s  (O R ) w ith  95% C o n fid e n ce  in te rv a ls
S y s te m ic  d isease n (%) O R  (95%  C I) X2-va lu e  (p -v a lu e )
T u b e rc u lo s is 62 (1 1 .7 )
A ll oral lesions 34 (54.8)
Oral candidiasis 25 (40.3)
P n e u m o n ia 14 (2 .6 )
A ll oral lesions 4 (28.6)
Oral candidiasis 2 (14.3)
H e rp e s  z o s te r 8 (1 .5 )
A ll oral lesions 2 (25.0)
Oral candidiasis 2 (25.0)
(Table 6 ). This association possibly reflects im m une dete­
rioration in  patients w ith oral candidiasis and  TB. This 
finding, which is in  keeping w ith th a t o f  N ittayananta et 
al. 2002 [46] w ho found significant association betw een 
the occurrence o f TB and  the presence o f oral candidiasis 
(OR 2.8; 95% CI 1.6-4.8; P < 0.01), and positive predic­
tive values o f any oral lesions and  oral candidiasis in  pre­
dicting TB o f 87% (95%  CI 73 .0-94.6) and  67% (95% CI 
51 .9-80 .0), respectively seem to im ply th a t oral candidia­
sis m ight be used as an  additional clinical m arker for TB 
together w ith clinical presentation o f  w eight loss w ith 
n ight sweats and  chest symptoms. Majority (25.9% ) 
reported history o f herpes zoster infection, 84 patients 
(15.8% ) pneum onia while cryptococcal m eningitis was 
reported by only 10 patients (1.9% ). However, there was 
no  statistically significant difference betw een prevalence 
o f oral lesions and  history o f opportunistic systemic dis­
eases (P > 0.05). The lim itation on  this part o f the study 
was dependency on  patients to recall previous opportun­
istic disease.
Lastly, the significant association betw een occurrence of 
oral lesions w ith CD4+ counts < 200 cells/m m 3 and  WHO 
clinical stage o f HIV disease (Table 1) found in  this study 
underscores the prognostic significance o f these m anifes­
tations in  HIV disease.
Conclusion
In this group o f HIV-infected patients, adult patients 
receiving HAART predom inantly  com bination  o f  stavu- 
dine, lam ivudine and nevirapine for a period o f less than  
a year, had a significantly lower prevalence o f oral lesions, 
particularly oral candidiasis and oral hairy leukoplakia 
tha t was observed. There was also an  insignificant increase 
in  prevalence o f oral warts and m ucosal hyper pigm enta­
tion, while the prevalence o f o ther oral lesions was 
unchanged. However there was no  significant change in  
occurrence o f oral lesions in  children receiving HAART. 
More studies preferably longitudinal need to  be con­
ducted for longer periods o f tim e in  order to  get a better
2.02 (1.19-3.46) 6.9 (0.008)
2.50 (1.44-4.34) 11.0 (0.001)
0 .6 I (0 .I9 -I.9 6 ) 0 .7 I (0.40)
0.54 (0 .I2 -2 .42) 0.68 (0 .4 I)
0 .5 I ( I.0 I-2 .5 3 ) 0 .7 I (0.32)
I.0 8  (0.22-5.45 0 .0 I (0.60)
picture on  the efficacy o f HAART in  reducing oral lesions 
in  bo th  children and  adults in  our setting.
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